WO2018129887A1 - 与原发性胆汁性胆管炎关联的白细胞介素21及其应用 - Google Patents
与原发性胆汁性胆管炎关联的白细胞介素21及其应用 Download PDFInfo
- Publication number
- WO2018129887A1 WO2018129887A1 PCT/CN2017/092504 CN2017092504W WO2018129887A1 WO 2018129887 A1 WO2018129887 A1 WO 2018129887A1 CN 2017092504 W CN2017092504 W CN 2017092504W WO 2018129887 A1 WO2018129887 A1 WO 2018129887A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pbc
- primary biliary
- biliary cholangitis
- patients
- allele
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention belongs to the field of immunology, and specifically relates to interleukin 21 (IL21) associated with primary biliary cholangitis and its use.
- IL21 interleukin 21
- PBC Primary biliary cholangitis
- AMA PBC-specific anti-mitochondrial antibodies
- the positive rate of AMA was found to be higher than 0.16% in middle-aged women. Medium is above 0.3% [5].
- a positive rate of AMA (PDC-E2) was found to be higher than 0.05% in 8126 adults (18-83 years old) in Guangdong, and higher than 0.15% in middle-aged women.
- a recent AMA screening of 19,012 residents in Shanghai found that 0.40% of men and 0.94% of women were positive for AMA, and 25 of them (0.13%) had PBC. With the aging of China's population, PBC will rapidly develop into a more common disease in China. It may reach 200,000 to 300,000 patients in 2025 and 35 to 500,000 patients by 2050.
- Ursodeoxycholic acid is the only drug that effectively controls early PBC patients (especially those with no jaundice), but there is no cure, and the only way to save patients with advanced PBC is Liver transplantation is performed. China is a country with high incidence of viral hepatitis.
- the clinical symptoms of PBC are similar to viral hepatitis.
- PBC patients are often misdiagnosed as viral hepatitis or drug-induced hepatitis in the early stage, which seriously affects the diagnosis and treatment of patients with PBC. Therefore, early diagnosis and treatment of PBC patients has important social significance.
- PBC has a strong genetic susceptibility, and the first-generation relatives of patients have a 100-fold higher incidence of PBC than the general population. According to reports from North America, Europe and Japan, the family incidence of PBC is 3.8-9%. In 2005, a large-scale survey in North America showed that the relative odds ratio of immediate family members of PBC patients was as high as 10.7. Analysis of identical twins in patients with PBC found a common incidence of 63%. In the past four years, our team has found three pairs of identical twin PBC patients in the survey of domestic PBC patients. The sister symptoms and onset time of the three pairs of patients are very close. Combined with international data, the identical pairs of PBC patients The common incidence rate of children 72.7%.
- GWAS genome-wide association analysis
- the North American PBC Cooperative Group which is a core member of the applicant, used GWAS and specific site high-density gene polymorphism analysis to conduct a cohort analysis of PBC patients and control populations in North America, confirming the genetic susceptibility of PBC and HLA-II antigens.
- IL12A, IL12RB2, STAT4, IRF5, ch17q12-21, MMEL1 and SPIB are closely related, and it is revealed that abnormalities in IL12 signaling pathway and Toll-like receptor (TLR)/TNF signaling pathway may lead to PBC .
- TLR Toll-like receptor
- the first technical problem to be solved by the present invention is to provide an application of IL21 in the preparation of a product for detecting or assisting detection, screening or predicting primary biliary cholangitis.
- the second technical problem to be solved by the present invention is to provide a series of single nucleotide polymorphism sites (SNPs) which are significantly associated with primary biliary cholangitis, and to find out which is associated with primary biliary cholangitis. Susceptibility correlates with the most prominent representative sites, thereby providing the use of said single nucleotide polymorphic sites (SNPs) for assessing susceptibility to primary biliary cholangitis.
- SNPs single nucleotide polymorphism sites
- a third technical problem to be solved by the present invention is to provide an application of IL21 in the preparation of an animal model of PBC.
- a fourth technical problem to be solved by the present invention is to provide an application of IL21 in the preparation of a therapeutic drug for PBC.
- the technical solution adopted by the present invention is:
- the application of IL21 in preparing a product for detecting or assisting detection, screening or predicting primary biliary cholangitis is provided.
- the genome-wide association analysis showed that the gene polymorphism of IL21 was closely related to the pathogenesis of PBC.
- the second aspect provides a series of single nucleotide polymorphisms of IL21 that are significantly associated with susceptibility to primary biliary cholangitis.
- the study was performed on 1122 Chinese Han PBC patients and 4036 normal subjects.
- the HumanOmniZhongHua-8 (v1.1) scan was used to analyze the genome-wide association data, and the gene polymorphism (SNP) was classified.
- SNP gene polymorphism
- PLINK software was used to compare all the polymorphic loci. The frequency of multiple SNPs of the IL21 gene was significantly different between the PBC and the normal population.
- the single nucleotide polymorphism of IL21 which is significantly associated with susceptibility to primary biliary cholangitis, is: rs17005934, allele is C/T; rs17005953, allele is T/C; rs28517551, allele Because A/G; rs925550, the allele is A/C; rs60318098, the allele is G/A; rs1026157, the allele is G/T; rs6811183, and the allele is T/G.
- the present invention finds a linkage relationship between a plurality of SNPs and rs925550 and rs17005934 by performing linkage disequilibrium analysis on SNPs at the IL21 site. Sequenom's iPlex method was used to verify the rs925550 and rs17005934 polymorphism sites; and the Impute2 and PLINK software were used to perform the logistic regression principle. The gender was used as the covariate and analyzed by the additive effect model; similarly, significant differences were found. All of the SNPs in Table 1 are genetic polymorphic sites that are significantly different between PBC and control and can be used for risk prediction of PBC.
- the present invention analyzes and evaluates the relationship between each SNP locus and primary biliary cholangitis by using PLINK software, logistic regression principle, and calculates the relative risk (ORd ratio, OR) of the dangerous allele and 95 The % confidence interval yields a dangerous allele for this series of SNP loci.
- the risk alleles of the SNP locus of IL21 are: rs17005934 polymorphism is C; s17005953, polymorphism is T; rs28517551 polymorphism is A; rs925550 polymorphism is A; The rs60318098 polymorphism site is G; rs1026157, the polymorphism site is G; the rs6811183 polymorphism site is T.
- the present invention specifically analyzes the presence of IL21 in 30 patients with PBC, 30 patients with autoimmune hepatitis (AIH), 25 patients with chronic hepatitis B (CHB), and 6 healthy controls (HC).
- AIH autoimmune hepatitis
- CHB chronic hepatitis B
- HC healthy controls
- the expression of IL21 protein was measured in liver tissue sections. It was found that IL21 was significantly increased in the liver tissue of PBC patients (P ⁇ 0.01). The expression level of IL21 was positively correlated with the degree of inflammation and fibrosis of liver tissue in PBC patients.
- an animal model established in the present invention introduces IL21 expression to prepare a PBC animal model, and the model is used for screening of a PBC therapeutic drug.
- the present invention has the following features and advantages:
- the present invention finds for the first time that multiple polymorphisms of IL21 are significantly associated with the occurrence of PBC, and can be used as one of the indicators for predicting the risk of PBC.
- IL21 is significantly elevated in the liver tissue of PBC patients and is useful for PBC targeted therapy. Target.
- FIG. 1 is a correlation diagram of a single nucleotide polymorphism site of the IL21 gene region and PBC determined in Example 1.
- the abscissa "Position on chr” is a position on a chromosome (unit: Mb);
- the coordinates are the P value of the single nucleotide polymorphism site associated with PBC (-log10 (p-value)), the right Recombination rate is the recombination rate, the unit (CM/Mb); the representative site rs925550 to ⁇ Said.
- Figure 2 is a histochemical analysis of IL21 in 30 patients with PBC, 30 patients with autoimmune hepatitis (AIH), 25 patients with chronic hepatitis B (CHB), and 6 healthy controls (HC).
- Expression in. 2A is the expression of IL21 in a liver tissue section of a patient with PBC in Example 3.
- 2B is the expression of IL21 in the liver tissue section of a patient with AIH in Example 3.
- 2C is the expression of IL21 in liver tissue sections of a patient with CHB in Example 3.
- 2D is the expression of IL21 in a liver tissue section of an HC tissue in Example 3.
- FIG. 2E is a statistical analysis of the expression of IL21 in liver tissue sections of 30 patients with PBC, 30 patients with AIH, 25 patients with chronic hepatitis B (CHB), and 6 healthy controls (HC) in Example 3 ( ** is P ⁇ 0.01 and * is P ⁇ 0.05).
- Fig. 2F is a result of analysis of the correlation between the expression of IL21 in liver tissue sections of 30 PBC patients and the degree of inflammation of liver tissue in PBC patients in Example 3.
- Fig. 2G is a result of analysis of the correlation between the expression of IL21 in liver tissue sections of 30 PBC patients and the degree of liver tissue fibrosis in PBC patients in Example 3.
- the HumanOmniZhongHua-8 (v1.1) analysis kit manufactured by Illumina Co., Ltd. includes a chip and a reagent.
- Phosphate buffer 8 g NaCl, 0.2 g KCl, 0.24 g KH 2 PO 4 , 3.628 g Na 2 HPO 4 ⁇ 12H 2 O, double distilled water to 1 L;
- Tris-HCl buffer pH 8.0: 30.3g Tris base dissolved in 200ml of double distilled water, hydrochloric acid to adjust the pH to 8.0, to a volume of 250ml;
- nuclear lysis buffer (Nuclei Lysis Buffer, 500ml): 40ml 5M NaCl, 2ml 0.5M EDTA (pH 8.0), 5ml 1M Tris-HCl (pH 8.0), 453ml double distilled water;
- Proteinase K buffer (Proteinase K buffer, 100ml): 50ml glycerol, 100ul 1M Tris-HCl (pH 7.5), 200 ⁇ l 1M CaCl 2 , 47ml double distilled water;
- Proteinase K (Proteinase K Solution, 10mg / ml): 100mg proteinase K powder dissolved in 10ml proteinase K buffer;
- TE buffer 1ml 1M Tris-HCl buffer (pH 8.0), 0.2ml 0.5M EDTA (pH 8.0), double distilled water to 100ml;
- TAE buffer 242g Tris-base, 57.1ml glacial acetic acid, 200ml 0.5M EDTA (pH 8.0), double distilled water to 1L.
- the present invention discovers the association of the IL21 gene locus with primary biliary cholangitis by the following methods and procedures.
- Non-anticoagulant therapy of patients and normal subjects was collected by non-anticoagulative collection tubes from various hospitals.
- the collection tube was centrifuged to separate serum and blood clots.
- the serum of the upper layer of the thawed blood sample was gently mixed with a pipette in a clean bench, and each was placed in four 1.5 ml screw cap storage tubes and stored at -80 °C.
- the HumanOmniZhongHua-8 (v1.1) chip was purchased from ILLUMINA, and the classification was carried out in accordance with the requirements of the product method. The exact steps are based on the experimental steps of the Illumina HumanOmniZhongHua-8 (v1.1) chip. The relevant description can be found in the published literature [Adler, AJ, Wiley, GB, Gaffney, PM Infinium Assay for Large-scale SNP Genotyping Applications .J.Vis.Exp. (81), e50683, doi: 10.3791/50683 (2013).]. Each DNA sample was treated at 200 nanograms (ng) in strict accordance with the experimental procedure described in the Illumina HumanOmniZhongHua-8 (v1.1) chip.
- the HumanOmniZhongHua-8 (v1.1) chip typing data was processed and output by the BeylStudio software of ILLUMINA, and the associated data analysis was performed according to the published literature [Zuo, X. et al. Whole-exome SNP array identification 15 new susceptibility loci for psoriasis.Nat Commun 6,6793,2015].
- the classification data output by BeadStudio is analyzed by PLINK, and the duplicate and affinity samples are excluded according to the pairwise identity-by-state. Using smartpca software, the heterogeneous samples were excluded according to the principle component analysis. The results of 1,122 PBC patients and 4,036 normal controls were used for statistical analysis.
- SNPs with a success rate of less than 98% exclude SNPs with a minimum allele frequency (MAF) of less than 0.01 in the analysis sample, and exclude Hardy–Weinberg equilibrium values of P ⁇ 1 ⁇ 10 -4 in normal control samples. SNP. After exclusion, a total of 776,516 autosomal SNPs were used for comparison.
- PLINK software SNP correlation analysis uses the principle of linear regression, using gender as the covariate, using the additive allelic effect, assessing the significance of each SNP locus associated with PBC, and calculating the dangerous alleles.
- the relative risk of the gene (Odds ratio, OR) and the 95% confidence interval, the OR value, confidence interval and P value were obtained directly in the analysis, thereby obtaining the dangerous allele of the site.
- the significance level (P value) associated with each PBC in the SNP chip was calculated by genome-wide association (GWAS) analysis, and the chromosomal region with potential association with PBC was found according to the significance level (P value less than 0.0001). And obtain a single nucleotide polymorphism site and its allele that are significantly associated with PBC susceptibility.
- the SNP calculation (Imputation) is based on the results of the Han people in the thousand human genome project (Reference), using IMPUTE2 software, combined with the results of 1,122PBC patients and 4,036 normal controls.
- the series of single nucleotide polymorphisms and their alleles are: rs17005934, allele is C/T; rs17005953, allele is T/C; rs28517551, allele is A/G; rs925550 The allele is A/C; rs60318098, the allele is G/A; rs1026157, the allele is G/T; rs6811183, the allele is T/G; the dangerous alleles are: rs17005934 polymorphism
- the sexual site is C; the rs17005953 polymorphism is T; the rs28517551 polymorphism is A; the rs925550 polymorphism is A; the rs60318098 polymorphism is G; the rs1026157 polymorphism is G
- the rs6811183 polymorphism site is T. Individuals carrying these dangerous alleles had a relative risk of developing PBC of 1.
- OR (95% CI) indicates the relative risk of developing PBC in individuals carrying disease-related haploids compared to individuals carrying normal haploids.
- the chromosomal location is referred to Human Genome GRCh37/hg19.
- PCR amplification primers and single base extension primers for the SNP site to be tested were designed using Sequenom Genothyping Tools and MassARRAY Assay Design software and synthesized by Integrated DNA Technologies.
- Primer 1 sequence ACGTTGGATGAAAGTGCAGACCAGGAAAAC;
- Primer 2 sequence ACGTTGGATGAAAGGGTGACTTCAGGGTAG;
- Primer 1 sequence ACGTTGGATGGGGAGGGTAATTAAAATTAG;
- Primer 2 sequence ACGTTGGATGGGGCAAATGAAGCCAATATA
- PCR amplification was performed using a multiplex PCR technique in a 384-well plate with a total volume of 5 ⁇ l per reaction system.
- a PCR master mix solution was prepared in a new 1.5 ml EP tube.
- the 384-well plate is a PCR reaction plate. Take out the prepared DNA sample 384-well plate, adjust the sample volume to 1 ⁇ L using a 24-channel sampler, and each template solution contains 20-50 ng of template DNA, Hotstar Taq 0.5U, 0.5 pmol of each amplification primer. , 0.1 ⁇ l of 25 mM dNTPs.
- the PCR reaction conditions were set on a 384-well compatible PCR machine: 94 ° C for 4 minutes; 94 ° C for 20 seconds, 56 ° C for 30 seconds, 72 ° C for 1 minute, 45 cycles; 72 ° C for 3 minutes; 4 ° C retention.
- a 384-well PCR reaction plate was placed on a PCR machine to initiate a PCR reaction.
- the PCR product was treated with SAP (shrimp alkaline phosphatase) to remove free dNTPs from the system.
- the single base extension reaction system contained 7 ⁇ l of the SAP-treated PCR product and 2 ⁇ l of the EXTEND Mix solution (wherein each of the extension reaction primer mixtures was 0.94 ⁇ l, the iPLEX enzyme was 0.041 ⁇ l, and the extension mixture was 0.2 ⁇ l).
- the PCR machine was started to perform a single base extension reaction.
- MassARRAY Nanodispenser RS1000 spotter was started and the resin extended extension was transferred to a 384 well SpectroCHIP chip.
- the spotted SpectroCHIP chip was analyzed using MALDI-TOF (matrix-assisted laser desorption/ionization–time of fligh), and the results were classified using TYPER 4.0 software (sequenom) and the results were output. . A total of 907 PBC samples and 2127 control samples gave valid results.
- the results of 907 PBC samples and 2127 control samples were statistically analyzed by gender as the common variable.
- the disease-related haploid (G) frequency of rs17005934 was significantly higher in the PBC (0.428) than in the control population (0.362), with a p-value of 1.25 ⁇ 10 -6 .
- the disease-related haploid (A) frequency of rs925550 was significantly higher in the PBC (0.427) than in the control population (0.353), with a p-value of 7.44 ⁇ 10 -8 .
- the GWAS results of 1,122 PBC patients and 4,036 normal controls were superimposed with the results of 907 PBC samples and 2127 control samples.
- the principle of fixed-effect model (I2 ⁇ 25%) was used.
- the statistical analysis included 2029 PBCs. Sample and 6163 control samples.
- the results showed that the disease-related haploid (G) frequency of rs17005934 was significantly higher in PBC than in the control group, with a p-value of 1.06 ⁇ 10 -11 and an odds ratio (96% CI) of 1.29 (1.21- 1.39);
- the disease-related haploid (A) frequency of rs925550 was significantly higher in PBC than in the control population, with a p-value of 3.87 ⁇ 10 -13 and a relative risk value (96% CI) of 1.31 (1.21-1.40) (see table 3).
- Table 3 Results of IL21 polymorphic loci rs17005934 and rs925550 in genome-wide association analysis and validation findings
- liver tissues including 30 patients with PBC, 30 patients with autoimmune hepatitis (AIH), and 25 patients with chronic hepatitis B (CHB) were ultrasound-guided liver biopsy at Shanghai Renji Hospital.
- the liver tissue of 6 healthy controls (HC) was from a liver transplant donor. Liver tissues were preserved in formalin and embedded in paraffin. The degree of inflammation and fibrosis of liver tissue was assessed according to the "Scheuer" scoring system.
- Liver tissue sections were soaked in sodium citrate buffer for 20 minutes;
- IL21 expression was significantly elevated in liver tissues of patients with PBC compared with hepatitis B, autoimmune hepatitis and normal liver tissue.
- IL21-positive cells are inflammatory hepatocytes and infiltrating inflammatory lymphocytes surrounding the portal area of the liver.
- the experimental results show that the number of IL21 positive cells is proportional to the degree of inflammation in the liver and the degree of fibrosis in the liver.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
- IL21在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用。
- IL21基因多态位点rs17005934的试剂在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用,rs17005934序列如序列表中的SEQ ID NO.1所示,其中,单核苷酸n为C的携带者原发性胆汁性胆管炎的风险高于等位基因T。
- IL21基因多态位点rs17005953的试剂在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用,rs17005953序列如序列表中的SEQ ID NO.2所示,其中,单核苷酸n为T的携带者原发性胆汁性胆管炎的风险高于等位基因C。
- IL21基因多态位点rs28517551的试剂在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用,rs28517551序列如序列表中的SEQ ID NO.3所示,其中,单核苷酸n为A的携带者原发性胆汁性胆管炎的风险高于等位基因G。
- IL21基因多态位点rs925550的试剂在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用rs925550序列如序列表中的SEQ ID NO.4所示,其中,单核苷酸n为A的携带者原发性胆汁性胆管炎的风险高于等位基因C。
- IL21基因多态位点rs60318098的试剂在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用,rs60318098序列如序列表中的SEQ ID NO.5所示,其中,单核苷酸n为G的携带者原发性胆汁性胆管炎的风险高于等位基因A。
- IL21基因多态位点rs1026157的试剂在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用,rs1026157序列如序列表中的SEQ ID NO.6所示,其中,单核苷酸n为G的携带者原发性胆汁性胆管炎的风险高于等位基因T。
- IL21基因多态位点rs6811183的试剂在制备检测或辅助检测、筛查或预测原发性胆汁性胆管炎的产品中的应用,rs6811183序列如序列表中的SEQ ID NO.7所示,其中,单核苷酸n为T的携带者原发性胆汁性胆管炎的风险高于等位基因G。
- IL21在制备PBC动物模型中的应用。
- IL21在制备PBC治疗药物方面的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710015507.8A CN106755461B (zh) | 2017-01-10 | 2017-01-10 | 与原发性胆汁性胆管炎关联的白细胞介素21及其应用 |
CN201710015507.8 | 2017-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018129887A1 true WO2018129887A1 (zh) | 2018-07-19 |
Family
ID=58948907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/092504 WO2018129887A1 (zh) | 2017-01-10 | 2017-07-11 | 与原发性胆汁性胆管炎关联的白细胞介素21及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN106755461B (zh) |
WO (1) | WO2018129887A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112695081A (zh) * | 2020-12-30 | 2021-04-23 | 中国医学科学院北京协和医院 | 原发性胆汁性胆管炎新的易感基因及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106755461B (zh) * | 2017-01-10 | 2019-04-30 | 东南大学 | 与原发性胆汁性胆管炎关联的白细胞介素21及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010102387A1 (en) * | 2009-03-09 | 2010-09-16 | University Health Network (Uhn) | Interleukin-12 polymorphisms for identifying risk for primary biliary cirrhosis |
CN103602671A (zh) * | 2013-10-16 | 2014-02-26 | 中国人民解放军第四军医大学 | 一种krt8基因外显子区域中snp位点及其确定方法 |
CN103749388A (zh) * | 2014-01-16 | 2014-04-30 | 中国科学技术大学 | 培育作为肝纤维化与原发性胆汁性肝硬化动物模型的IL-12p40(-/-)IL-2Rα(-/-)小鼠的方法 |
CN106755461A (zh) * | 2017-01-10 | 2017-05-31 | 东南大学 | 与原发性胆汁性胆管炎关联的白细胞介素21及其应用 |
-
2017
- 2017-01-10 CN CN201710015507.8A patent/CN106755461B/zh active Active
- 2017-07-11 WO PCT/CN2017/092504 patent/WO2018129887A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010102387A1 (en) * | 2009-03-09 | 2010-09-16 | University Health Network (Uhn) | Interleukin-12 polymorphisms for identifying risk for primary biliary cirrhosis |
CN103602671A (zh) * | 2013-10-16 | 2014-02-26 | 中国人民解放军第四军医大学 | 一种krt8基因外显子区域中snp位点及其确定方法 |
CN103749388A (zh) * | 2014-01-16 | 2014-04-30 | 中国科学技术大学 | 培育作为肝纤维化与原发性胆汁性肝硬化动物模型的IL-12p40(-/-)IL-2Rα(-/-)小鼠的方法 |
CN106755461A (zh) * | 2017-01-10 | 2017-05-31 | 东南大学 | 与原发性胆汁性胆管炎关联的白细胞介素21及其应用 |
Non-Patent Citations (3)
Title |
---|
LI, Y. Y.: "CXCL13 Promotes Intrahepatic CXCR5+ Lymphocyte Homing and Aber- rant B Cell Immune Responses in Primary Biliary Cirrhosis", HEPATOLOGY, vol. 61, no. 6, 30 June 2015 (2015-06-30), pages 1998 - 2007, XP055508585 * |
MELLS, G. F.: "Genome-wide association study identifies 12 new susceptibi- lity loci for primary biliary cirrhosis", NATURE GENETICS, vol. 43, no. 4, 30 April 2011 (2011-04-30), pages 329 - 332, XP055508575 * |
QIU, F .: "A genome-wide association study identifies six novel risk loci for primary biliary cholangitis", NATURE COMMUNICATIONS, vol. 1-8, 20 April 2017 (2017-04-20), XP055508593 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112695081A (zh) * | 2020-12-30 | 2021-04-23 | 中国医学科学院北京协和医院 | 原发性胆汁性胆管炎新的易感基因及其应用 |
CN112695081B (zh) * | 2020-12-30 | 2022-08-26 | 中国医学科学院北京协和医院 | 原发性胆汁性胆管炎新的易感基因及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106755461B (zh) | 2019-04-30 |
CN106755461A (zh) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6523375B2 (ja) | 肝臓病変を評価する方法 | |
Marcolongo et al. | A seven‐gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C | |
CN104745710A (zh) | 一种与原发性肝细胞癌辅助诊断相关的snp标志物及其应用 | |
CN102399898B (zh) | 一种与临床原因不明的非梗阻性无精子症辅助诊断相关的snp标志物及其应用 | |
WO2019075868A1 (zh) | 一种检测布鲁菌感染的方法及其应用 | |
WO2018129887A1 (zh) | 与原发性胆汁性胆管炎关联的白细胞介素21及其应用 | |
WO2018129888A1 (zh) | 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用 | |
CN108715893B (zh) | 一组与放疗引起的放射性脑损伤相关的snp标志物及其应用 | |
KR101206028B1 (ko) | 유방암 특이적 다형성 서열을 이용한 유방암의 진단방법,유방암 특이적인 폴리뉴클레오티드 및 상기 폴리뉴클레오티드가 고정되어 있는 마이크로어레이 | |
WO2018129886A1 (zh) | 与原发性胆汁性胆管炎关联的白细胞介素16及其应用 | |
Munshaw et al. | Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C‐infected drug users | |
CN110373457A (zh) | 一种用于溃疡性结肠炎诊断的mRNA标志物及其应用 | |
CN113308531B (zh) | Tex11基因致病性突变在制备检测非梗阻性无精子症诊断试剂盒中的应用 | |
CN112980949B (zh) | 一种用于鼻咽癌高危人群识别的snp标志物及其试剂盒和应用 | |
JP6494356B2 (ja) | 非アルコール性脂肪性肝疾患及び/又は非アルコール性脂肪肝炎の発症リスク及び/又は重症化リスクの判定方法、並びに該判定用オリゴヌクレオチドキット | |
CN107400708A (zh) | Xrcc1基因多态性在风湿性关节炎诊断有效性中的用途 | |
JP6128654B2 (ja) | 関節リウマチの新規遺伝因子としてのミエリン塩基性蛋白の利用 | |
CN104387457B (zh) | 慢性乙型和丁型肝炎病毒肝细胞受体编码基因slc10a1的新突变蛋白、编码基因及其应用 | |
CN105671198A (zh) | 检测肝糖原累积症iii型agl基因突变的试剂盒及其应用 | |
JP2006246881A (ja) | ウシ白血病発症に対する抵抗性の判定方法 | |
WO2023236189A1 (zh) | 利用非完整重组的t细胞受体核苷酸序列诊断t细胞淋巴瘤的方法及试剂盒 | |
CN104263822B (zh) | 一种与临床原因不明的noa辅助诊断相关的低频snv标志物及其应用 | |
CN108949947A (zh) | 与抗结核药物性肝损伤发生相关的细胞色素p450基因多态性位点 | |
CN106480211A (zh) | 一种用于检测睾丸癌易感性的试剂盒及其snp标志物 | |
CN116411068A (zh) | 与单纯法洛四联症相关的tbx1基因非编码突变及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17890853 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17890853 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17890853 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 14/05/2020) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17890853 Country of ref document: EP Kind code of ref document: A1 |